Aardvark Therapeutics, Inc. Common Stock
$5.38
-$0.15 (-2.71%)
$5.19Day Range$5.59
Key Statistics
Market Cap
$117.74M
Shares Outstanding
21.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 13, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$5.44
Day High
$5.59
Day Low
$5.19
Volume
129.8K
VWAP
$5.37
Prev Close
$5.53
Transactions
--
Acc. Volume
--
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
PHARMACEUTICAL PREPARATIONSSIC 283428 employees4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO, CA, 92122(858) 225-7696IPO Feb 13, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001774857
- Composite FIGI
- BBG01223DLB2
- Share Class FIGI
- BBG01223DLC1
- Ticker Root
- AARD
- SIC Code
- 2834
About Aardvark Therapeutics, Inc. Common Stock (AARD) Stock
Aardvark Therapeutics, Inc. Common Stock (AARD) closed the 2026-09-18 session at $5.38, down 2.71% versus the previous close (-0.15). The stock opened at $5.44 and traded between $5.19 and $5.59 during that session. Session trading volume was 130K shares. The volume-weighted average price (VWAP) is $5.37.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Aardvark Therapeutics, Inc. Common Stock has a market capitalization of $117.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AARD is listed on the XNAS exchange. The company employs approximately 28 people. Aardvark Therapeutics, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2025-02-13.
On this page you can find market AARD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.